SEARCH

SEARCH BY CITATION

References

  • Akhurst, R.J. (2002). TGF-beta antagonists: why suppress a tumor suppressor? J. Clin. Invest. 109, 15331536.
  • Albino, A.P., Davis, B.M., and Nanus, D.M. (1991). Induction of growth factor RNA expression in human malignant melanoma: markers of transformation. Cancer Res. 51, 48154820.
  • Arteaga, C.L. (2006). Inhibition of TGFbeta signaling in cancer therapy. Curr. Opin. Genet. Dev. 16, 3037.
  • Arteaga, C.L., Hurd, S.D., Winnier, A.R., Johnson, M.D., Fendly, B.M., and Forbes, J.T. (1993). Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J. Clin. Invest. 92, 25692576.
  • Bandyopadhyay, A., Lopez-Casillas, F., Malik, S.N., Montiel, J.L., Mendoza, V., Yang, J., and Sun, L.Z. (2002). Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft. Cancer Res. 62, 46904695.
  • Bandyopadhyay, A., Wang, L., Lopez-Casillas, F., Mendoza, V., Yeh, I.T., and Sun, L. (2005). Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer. Prostate 63, 8190.
  • Bandyopadhyay, A., Agyin, J.K., Wang, L., Tang, Y., Lei, X., Story, B.M., Cornell, J.E., Pollock, B.H., Mundy, G.R., and Sun, L.Z. (2006). Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res. 66, 67146721.
  • Berking, C., Takemoto, R., Schaider, H., Showe, L., Satyamoorthy, K., Robbins, P., and Herlyn, M. (2001). Transforming growth factor-beta1 increases survival of human melanoma through stroma remodeling. Cancer Res. 61, 83068316.
  • Bloethner, S., Chen, B., Hemminki, K., Muller-Berghaus, J., Ugurel, S., Schadendorf, D., and Kumar, R. (2005). Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. Carcinogenesis 26, 12241232.
  • Bottinger, E.P., and Kopp, J.B. (1998). Lessons from TGF-beta transgenic mice. Miner. Electrolyte Metab. 24, 154160.
  • De Caestecker, M.P., Piek, E., and Roberts, A.B. (2000). Role of transforming growth factor-beta signaling in cancer. J. Natl Cancer Inst. 92, 13881402.
  • DaCosta Byfield, S., Major, C., Laping, N.J., and Roberts, A.B. (2004). SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 65, 744752.
  • Daniotti, M., Oggionni, M., Ranzani, T. et al. (2004). BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene 23, 59685977.
  • Dennler, S., Andre, J., Alexaki, I., Li, A., Magnaldo, T., Ten Dijke, P., Wang, X.J., Verrecchia, F., and Mauviel, A. (2007). Induction of sonic hedgehog mediators by transforming growth factor-beta: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo. Cancer Res. 67, 69816986.
  • Derynck, R., and Zhang, Y.E. (2003). Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425, 577584.
  • Ten Dijke, P., and Hill, C.S. (2004). New insights into TGF-beta-Smad signalling. Trends Biochem. Sci. 29, 265273.
  • Elliott, R.L., and Blobe, G.C. (2005). Role of transforming growth factor Beta in human cancer. J. Clin. Oncol. 23, 20782093.
  • Van Elsas, A., Zerp, S., Van Der Flier, S., Kruse-Wolters, M., Vacca, A., Ruiter, D.J., and Schrier, P. (1995). Analysis of N-ras mutations in human cutaneous melanoma: tumor heterogeneity detected by polymerase chain reaction/single-stranded conformation polymorphism analysis. Recent Results Cancer Res. 139, 5767.
  • Feng, X.H., and Derynck, R. (2005). Specificity and versatility in TGF-beta signaling through Smads. Annu. Rev. Cell Dev. Biol. 21, 659693.
  • Friese, M.A., Wischhusen, J., Wick, W., Weiler, M., Eisele, G., Steinle, A., and Weller, M. (2004). RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res. 64, 75967603.
  • Gaspar, N.J., Li, L., Kapoun, A.M. et al. (2007). Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness. Mol. Pharmacol. 72, 152161.
  • Ge, R., Rajeev, V., Ray, P. et al. (2006). Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo. Clin. Cancer Res. 12, 43154330.
  • Goydos, J.S., Mann, B., Kim, H.J., Gabriel, E.M., Alsina, J., Germino, F.J., Shih, W., and Gorski, D.H. (2005). Detection of B-RAF and N-RAS mutations in human melanoma. J. Am. Coll. Surg. 200, 362370.
  • Halder, S.K., Beauchamp, R.D., and Datta, P.K. (2005). A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia 7, 509521.
  • Hannon, G.J., and Beach, D. (1994). p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371, 257261.
  • Hoek, K.S., Schlegel, N.C., Brafford, P. et al. (2006). Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res. 19, 290302.
  • Houghton, A.N., and Polsky, D. (2002). Focus on melanoma. Cancer Cell 2, 275278.
  • Ijland, S.A., Jager, M.J., Heijdra, B.M., Westphal, J.R., and Peek, R. (1999). Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines. Melanoma Res. 9, 445450.
  • Inman, G.J., Nicolas, F.J., Callahan, J.F., Harling, J.D., Gaster, L.M., Reith, A.D., Laping, N.J., and Hill, C.S. (2002). SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 62, 6574.
  • Janji, B., Melchior, C., Gouon, V., Vallar, L., and Kieffer, N. (1999). Autocrine TGF-beta-regulated expression of adhesion receptors and integrin-linked kinase in HT-144 melanoma cells correlates with their metastatic phenotype. Int. J. Cancer 83, 255262.
  • Javelaud, D., and Mauviel, A. (2004). Mammalian transforming growth factor-betas: Smad signaling and physio-pathological roles. Int. J. Biochem. Cell Biol. 36, 11611165.
  • Javelaud, D., and Mauviel, A. (2005). Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis. Oncogene 24, 57425750.
  • Javelaud, D., Delmas, V., Moller, M., Sextius, P., Andre, J., Menashi, S., Larue, L., and Mauviel, A. (2005). Stable overexpression of Smad7 in human melanoma cells inhibits their tumorigenicity in vitro and in vivo. Oncogene 24, 76247629.
  • Javelaud, D., Mohammad, K.S., McKenna, C.R. et al. (2007). Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. Cancer Res. 67, 23172324.
  • Kang, Y., Prentice, M.A., Mariano, J.M., Davarya, S., Linnoila, R.I., Moody, T.W., Wakefield, L.M., and Jakowlew, S.B. (2000). Transforming growth factor-beta 1 and its receptors in human lung cancer and mouse lung carcinogenesis. Exp. Lung Res. 26, 685707.
  • Kang, Y., He, W., Tulley, S., Gupta, G.P., Serganova, I., Chen, C.R., Manova-Todorova, K., Blasberg, R., Gerald, W.L., and Massague, J. (2005). Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl Acad. Sci. USA 102, 1390913914.
  • Kim, C.J., Reintgen, D.S., and Balch, C.M. (2002). The new melanoma staging system. Cancer Control 9, 915.
  • Komesli, S., Vivien, D., and Dutartre, P. (1998). Chimeric extracellular domain type II transforming growth factor (TGF)-beta receptor fused to the Fc region of human immunoglobulin as a TGF-beta antagonist. Eur. J. Biochem. 254, 505513.
  • Komuro, A., Imamura, T., Saitoh, M., Yoshida, Y., Yamori, T., Miyazono, K., and Miyazawa, K. (2004). Negative regulation of transforming growth factor-beta (TGF-beta) signaling by WW domain-containing protein 1 (WWP1). Oncogene 23, 69146923.
  • Krakowski, A.R., Laboureau, J., Mauviel, A., Bissell, M.J., and Luo, K. (2005). From the cover: cytoplasmic SnoN in normal tissues and nonmalignant cells antagonizes TGF-{beta} signaling by sequestration of the Smad proteins. Proc. Natl Acad. Sci. USA 102, 1243712442.
  • Krasagakis, K., Garbe, C., Schrier, P.I., and Orfanos, C.E. (1994). Paracrine and autocrine regulation of human melanocyte and melanoma cell growth by transforming growth factor beta in vitro. Anticancer Res. 14, 25652571.
  • Krasagakis, K., Tholke, D., Farthmann, B., Eberle, J., Mansmann, U., and Orfanos, C.E. (1998). Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma. Br. J. Cancer 77, 14921494.
  • Krasagakis, K., Kruger-Krasagakes, S., Fimmel, S., Eberle, J., Tholke, D., Von Der Ohe, M., Mansmann, U., and Orfanos, C.E. (1999). Desensitization of melanoma cells to autocrine TGF-beta isoforms. J. Cell. Physiol. 178, 179187.
  • Kretzschmar, M., Doody, J., Timokhina, I., and Massagué, J. (1999). A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. Genes Dev. 13, 804816.
  • Lahn, M., Kloeker, S., and Berry, B.S. (2005). TGF-beta inhibitors for the treatment of cancer. Expert. Opin. Investig. Drugs 14, 629643.
  • Lehmann, K., Janda, E., Pierreux, C.E., Rytomaa, M., Schulze, A., McMahon, M., Hill, C.S., Beug, H., and Downward, J. (2000). Raf induces TGFbeta production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells. Genes Dev. 14, 26102622.
  • Leivonen, S.K., and Kahari, V.M. (2007). Transforming growth factor-beta signaling in cancer invasion and metastasis. Int. J. Cancer 121, 21192124.
  • Li, G., Satyamoorthy, K., Meier, F., Berking, C., Bogenrieder, T., and Herlyn, M. (2003). Function and regulation of melanoma-stromal fibroblast interactions: when seeds meet soil. Oncogene 22, 31623171.
  • Li, M.O., Wan, Y.Y., Sanjabi, S., Robertson, A.K., and Flavell, R.A. (2006). Transforming growth factor-beta regulation of immune responses. Annu. Rev. Immunol. 24, 99146.
  • Libra, M., Malaponte, G., Navolanic, P.M. et al. (2005). Analysis of BRAF mutation in primary and metastatic melanoma. Cell Cycle 4, 13821384.
  • Liu, X., Sun, Y., Weinberg, R.A., and Lodish, H.F. (2001). Ski/Sno and TGF-beta signaling. Cytokine Growth Factor Rev. 12, 18.
  • Liu, G., Zhang, F., Lee, J., and Dong, Z. (2005). Selective induction of interleukin-8 expression in metastatic melanoma cells by transforming growth factor-beta 1. Cytokine 31, 241249.
  • Lopez-Bergami, P., Huang, C., Goydos, J.S. et al. (2007). Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell 11, 447460.
  • Maldonado, J.L., Fridlyand, J., Patel, H., Jain, A.N., Busam, K., Kageshita, T., Ono, T., Albertson, D.G., Pinkel, D., and Bastian, B.C. (2003). Determinants of BRAF mutations in primary melanomas. J. Natl Cancer Inst. 95, 18781890.
  • Massagué, J., and Chen, Y.G. (2000). Controlling TGF-beta signaling. Genes Dev. 14, 627644.
  • Massague, J., and Gomis, R.R. (2006). The logic of TGFbeta signaling. FEBS Lett. 580, 28112820.
  • Mauviel, A., Javelaud, D., Le Scolan, E., Alexaki, V.I., and Luo, K. (2007a). C-SKI expression in human melanoma cells does not antagonize TGF-beta-dependent transcriptional responses. J. Investig. Dermatol. 127(Suppl. 2), S50.
  • Mauviel, A., Javelaud, D., Mohammad, K.S. et al. (2007b). The transforming growth factor beta receptor I kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastasis. J. Investig. Dermatol. 127(Suppl. 2), S48.
  • Miyoshi, E., Nishikawa, A., Ihara, Y., Saito, H., Uozumi, N., Hayashi, N., Fusamoto, H., Kamada, T., and Taniguchi, N. (1995). Transforming growth factor beta up-regulates expression of the N-acetylglucosaminyltransferase V gene in mouse melanoma cells. J. Biol. Chem. 270, 62166220.
  • Mourskaia, A.A., Northey, J.J., and Siegel, P.M. (2007). Targeting aberrant TGF-beta signaling in pre-clinical models of cancer. Anticancer Agents Med. Chem. 7, 504514.
  • Moustakas, A., Souchelnytskyi, S., and Heldin, C.H. (2001). Smad regulation in TGF-beta signal transduction. J. Cell Sci. 114, 43594369.
  • Nam, J.S., Suchar, A.M., Kang, M.J. et al. (2006). Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer. Cancer Res. 66, 63276335.
  • Oft, M., Heider, K.H., and Beug, H. (1998). TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr. Biol. 8, 12431252.
  • Oft, M., Akhurst, R.J., and Balmain, A. (2002). Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat. Cell Biol. 4, 487494.
  • Park, S.S., Li, L., Korn, T.S., Mitra, M.M., and Niederkorn, J.Y. (1996). Effect of transforming growth factor-beta on plasminogen activator production of cultured human uveal melanoma cells. Curr. Eye Res. 15, 755763.
  • Peng, S.B., Yan, L., Xia, X. et al. (2005). Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition. Biochemistry 44, 22932304.
  • Platz, A., Ringborg, U., Brahme, E.M., and Lagerlof, B. (1994). Melanoma metastases from patients with hereditary cutaneous malignant melanoma contain a high frequency of N-ras activating mutations. Melanoma Res. 4, 169177.
  • Poser, I., Rothhammer, T., Dooley, S., Weiskirchen, R., and Bosserhoff, A.K. (2005). Characterization of Sno expression in malignant melanoma. Int. J. Oncol. 26, 14111417.
  • Poulalhon, N., Farge, D., Roos, N., Tacheau, C., Neuzillet, C., Michel, L., Mauviel, A., and Verrecchia, F. (2006). Modulation of collagen and MMP-1 gene expression in fibroblasts by the immunosuppressive drug rapamycin. A direct role as an antifibrotic agent?. J. Biol. Chem. 281, 3304533052.
  • Pulaski, L., Landstrom, M., Heldin, C.H., and Souchelnytskyi, S. (2001). Phosphorylation of Smad7 at Ser-249 does not interfere with its inhibitory role in transforming growth factor-beta -dependent signaling but affects Smad7-dependent transcriptional activation. J. Biol. Chem. 276, 1434414349.
  • Reed, J.A., McNutt, N.S., Prieto, V.G., and Albino, A.P. (1994). Expression of transforming growth factor-beta2 in malignant melanoma correlates with the depth of tumor invasion. Am. J. Pathol. 145, 97104.
  • Reed, J.A., Bales, E., Xu, W., Okan, N.A., Bandyopadhyay, D., and Medrano, E.E. (2001). Cytoplasmic localization of the oncogenic protein ski in human cutaneous melanomas in vivo: functional implications for transforming growth factor Beta signaling. Cancer Res. 61, 80748078.
  • Reguly, T., and Wrana, J.L. (2003). In or out? The dynamics of Smad nucleocytoplasmic shuttling Trends Cell Biol. 13, 216220.
  • Reynisdottir, I., Polyak, K., Iavarone, A., and Massague, J. (1995). Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev. 9, 18311845.
  • Rodeck, U., Melber, K., Kath, R., Menssen, H.D., Varello, M., Atkinson, B., and Herlyn, M. (1991). Constitutive expression of multiple growth factor genes by melanoma cells but not normal melanocytes. J. Invest. Dermatol. 97, 2026.
  • Rodeck, U., Bossler, A., Graeven, U., Fox, F.E., Nowell, P.C., Knabbe, C., and Kari, C. (1994). Transforming growth factor beta production and responsiveness in normal human melanocytes and melanoma cells. Cancer Res. 54, 575581.
  • Rodeck, U., Nishiyama, T., and Mauviel, A. (1999). Independent regulation of growth and SMAD-mediated transcription by transforming growth factor beta in human melanoma cells. Cancer Res. 59, 547550.
  • Rothhammer, T., Poser, I., Soncin, F., Bataille, F., Moser, M., and Bosserhoff, A.K. (2005). Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res. 65, 448456.
  • Rothhammer, T., Bataille, F., Spruss, T., Eissner, G., and Bosserhoff, A.K. (2007). Functional implication of BMP4 expression on angiogenesis in malignant melanoma. Oncogene 26, 41584170.
  • Rubtsov, Y.P., and Rudensky, A.Y. (2007). TGFbeta signalling in control of T-cell-mediated self-reactivity. Nat Rev Immunol 7, 443453.
  • Salomon, D.S. (2006). Melanoma pathogenesis and nodal: a partial picture? Nat. Med. 12, 1231.
  • Saunier, E.F., and Akhurst, R.J. (2006). TGF beta inhibition for cancer therapy. Curr. Cancer Drug Targets 6, 565578.
  • Schadendorf, D., Moller, A., Algermissen, B., Worm, M., Sticherling, M., and Czarnetzki, B.M. (1993). IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J. Immunol. 151, 26672675.
  • Schlingensiepen, K.H., Schlingensiepen, R., Steinbrecher, A., Hau, P., Bogdahn, U., Fischer-Blass, B., and Jachimczak, P. (2006). Targeted tumor therapy with the TGF-beta2 antisense compound AP 12009. Cytokine Growth Factor Rev. 17(1–2), 129139.
  • Schlingensiepen, K.H., Fischer-Blass, B., Schmaus, S., and Ludwig, S. (2008). Antisense therapeutics for tumor treatment: the TGF-beta2 inhibitor AP 12009 in clinical development against malignant tumors. Recent Results Cancer Res. 177, 137150.
  • Shah, A.H., Tabayoyong, W.B., Kundu, S.D., Kim, S.J., Van Parijs, L., Liu, V.C., Kwon, E., Greenberg, N.M., and Lee, C. (2002). Suppression of tumor metastasis by blockade of transforming growth factor beta signaling in bone marrow cells through a retroviral-mediated gene therapy in mice. Cancer Res. 62, 71357138.
  • Shi, Y., and Massague, J. (2003). Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113, 685700.
  • Shi, M.J., Park, S.R., Kim, P.H., and Stavnezer, J. (2001). Roles of Ets proteins, NF-kappaB and nocodazole in regulating induction of transcription of mouse germline Ig alpha RNA by transforming growth factor-beta1. Int. Immunol. 13, 733746.
  • Tacheau, C., Michel, L., Farge, D., Mauviel, A., and Verrecchia, F. (2007). Involvement of ERK signaling in halofuginone-driven inhibition of fibroblast ability to contract collagen lattices. Eur. J. Pharmacol. 573, 6569.
  • Tojo, M., Hamashima, Y., Hanyu, A., Kajimoto, T., Saitoh, M., Miyazono, K., Node, M., and Imamura, T. (2005). The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta. Cancer Sci 96, 791800.
  • Topczewska, J.M., Postovit, L.M., Margaryan, N.V., Sam, A., Hess, A.R., Wheaton, W.W., Nickoloff, B.J., Topczewski, J., and Hendrix, M.J. (2006). Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat. Med. 12, 925932.
  • Uhl, M., Aulwurm, S., Wischhusen, J. et al. (2004). SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 64, 79547961.
  • Uribe, P., Wistuba I.I., and Gonzalez, S. (2003). BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am. J. Dermatopathol. 25, 365370.
  • Van Belle, P., Rodeck, U., Nuamah, I., Halpern, A.C., and Elder, D.E. (1996). Melanoma-associated expression of transforming growth factor-beta isoforms. Am. J. Pathol. 148, 18871894.
  • Van‘t Veer, L.J., Burgering, B.M., Versteeg, R., Boot, A.J., Ruiter, D.J., Osanto, S., Schrier, P.I., and Bos, J.L. (1989). N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol. Cell. Biol. 9, 31143116.
  • Verrecchia, F., and Mauviel, A. (2004). TGF-beta and TNF-alpha: antagonistic cytokines controlling type I collagen gene expression. Cell. Signal. 16, 873880.
  • Verrecchia, F., Pessah, M., Atfi, A., and Mauviel, A. (2000). Tumor necrosis factor-alpha inhibits transforming growth factor-beta/ Smad signaling in human dermal fibroblasts via AP-1 activation. J. Biol. Chem. 275, 3022630231.
  • Verrecchia, F., Tacheau, C., Schorpp-Kistner, M., Angel, P., and Mauviel, A. (2001). Induction of the AP-1 members c-Jun and JunB by TGF-beta/Smad suppresses early Smad-driven gene activation. Oncogene 20, 22052211.
  • Verrecchia, F., Tacheau, C., Wagner, E.F., and Mauviel, A. (2003). A central role for the JNK pathway in mediating the antagonistic activity of pro-inflammatory cytokines against transforming growth factor-beta-driven SMAD3/4-specific gene expression. J. Biol. Chem. 278, 15851593.
  • Vilchis-Landeros, M.M., Montiel, J.L., Mendoza, V., Mendoza-Hernandez, G., and Lopez-Casillas, F. (2001). Recombinant soluble betaglycan is a potent and isoform-selective transforming growth factor-beta neutralizing agent. Biochem. J. 355, 215222.
  • Wahl, S.M. (2007). Transforming growth factor-beta: innately bipolar. Curr. Opin. Immunol. 19, 5562.
  • Wakefield, L.M., and Roberts, A.B. (2002). TGF-beta signaling: positive and negative effects on tumorigenesis. Curr. Opin. Genet. Dev. 12, 2229.
  • Wu, R.S., Kobie, J.J., Besselsen, D.G., Fong, T.C., Mack, V.D., McEarchern, J.A., and Akporiaye, E.T. (2001). Comparative analysis of IFN-gamma B7.1 and antisense TGF-beta gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma. Cancer Immunol. Immunother. 50, 229240.
  • Xavier, S., Piek, E., Fujii, M. et al. (2004). Amelioration of radiation-induced fibrosis: inhibition of transforming growth factor-beta signaling by halofuginone. J. Biol. Chem. 279, 1516715176.
  • Yin, J.J., Selander, K., Chirgwin, J.M., Dallas, M., Grubbs, B.G., Wieser, R., Massagué, J., Mundy, G.R., and Guise, T.A. (1999). TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103, 197206.